(Reuters)-Oxford University said on Tuesday that it has suspended a small trial in the UK to test the application of the COVID-19 vaccine developed in cooperation with AstraZeneca Plc in children and adolescents as it is waiting Get more data on rare blood clotting problems in adults receiving the vaccine. shooting.
The suspension of the trial is the latest blow to the vaccine, which has been hailed as a milestone in the fight against the pandemic, and several countries have previously restricted it based on reports of post-vaccination medical problems.
The University of Oxford said that there were no safety concerns in the pediatric trial, adding that it would wait for guidance from the UK drug watchdog before proceeding with further vaccinations.
The university said in February that it plans to include 300 6-1
The European Medicines Agency (EMA) is currently reviewing reports of an extremely rare type of cerebral thrombosis (called cerebral venous sinus thrombosis (CVST)) following the AstraZeneca shooting, and is expected to announce its discovery on Wednesday or Thursday.
A senior EMA official stated that there is a clear link between the vaccine and CVST, although the direct cause of the clotting is not yet known.
The World Health Organization (WHO) and other regulatory agencies are closely studying the latest data on AstraZeneca’s vaccines. The organization said on Tuesday that it hopes there is no reason to change its assessment, believing that the benefits of vaccination outweigh any risks.
The Anglo-Swiss pharmaceutical company has been plagued by disputes with European governments over production, supply, possible side effects, and the pros and cons of vaccines.
Anthony Fauci, a top US infectious disease doctor, told Reuters last week that the US might not need AstraZeneca’s vaccine even if it gets regulatory approval.
Reporting by Aishwarya Nair, Manas Mishra and Pushkala Aripaka in Bangalore; Chris Reese and Ramakrishnan M.